← All trials
NCT04524273
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2020
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 28, 2024
- First posted
- Aug 24, 2020
- Last posted
- Sep 17, 2020
- Enrollment
- 252
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Viela BioLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.